title: Clinical application of the 70-gene profile: the MINDACT trial.
abstract: The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.
authors.affiliation: Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium.
authors.forename: Fatima
authors.initials: F
authors.lastname: Cardoso
authors.forename: Laura
authors.initials: L
authors.lastname: Van't Veer
authors.forename: Emiel
authors.initials: E
authors.lastname: Rutgers
authors.forename: Sherene
authors.initials: S
authors.lastname: Loi
authors.forename: Stella
authors.initials: S
authors.lastname: Mook
authors.forename: Martine J
authors.initials: MJ
authors.lastname: Piccart-Gebhart
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D003657:Decision Making; D005240:Feasibility Studies; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D054928:Validation Studies as Topic